Sanofi (SNY) Income Statement Analysis

See more : JYSKE INVEST FJERNØSTEN AKTIER SRI KL (JYIFJASRIKL.CO) Income Statement Analysis – Financial Results

Complete financial analysis of Sanofi (SNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sanofi, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.

You may be interested

Shijiazhuang Kelin Electric Co., Ltd. (603050.SS) Income Statement Analysis – Financial Results
Truscott Mining Corporation Limited (TRM.AX) Income Statement Analysis – Financial Results
SPI Energy Co., Ltd. (SPI) Income Statement Analysis – Financial Results
Turkiye Garanti Bankasi A.S. (GARAN.IS) Income Statement Analysis – Financial Results
O.B.System Inc. (5576.T) Income Statement Analysis – Financial Results

Sanofi (SNY)

Industry: Drug Manufacturers - General

Sector: Healthcare

Website: https://www.sanofi.com

About Sanofi

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999
Revenue	46.03B	45.39B	39.18B	37.37B	37.63B	35.68B	36.22B	34.70B	34.86B	32.00B	31.29B	35.96B	35.06B	32.04B	30.75B	28.82B	29.25B	29.49B	28.49B	15.03B	8.03B	7.46B	6.49B	5.96B	5.35B
Cost of Revenue	14.24B	13.69B	12.26B	12.16B	11.98B	11.32B	11.45B	10.70B	10.92B	10.23B	10.29B	11.08B	10.90B	8.72B	7.88B	7.34B	7.58B	7.59B	7.56B	3.75B	1.43B	1.38B	1.25B	1.44B	1.49B
Gross Profit	31.80B	31.70B	26.92B	25.21B	25.66B	24.36B	24.77B	24.00B	23.94B	21.77B	21.00B	24.88B	24.16B	23.32B	22.87B	21.48B	21.67B	21.90B	20.93B	11.28B	6.61B	6.08B	5.24B	4.52B	3.86B
Gross Profit Ratio	69.07%	69.83%	68.72%	67.47%	68.18%	68.27%	68.40%	69.16%	68.68%	68.03%	67.10%	69.20%	68.90%	72.79%	74.37%	74.55%	74.08%	74.27%	73.47%	75.05%	82.26%	81.50%	80.69%	75.82%	72.11%
Research & Development	6.73B	6.71B	5.69B	5.53B	6.02B	6.35B	5.57B	5.23B	5.08B	4.67B	4.61B	4.91B	4.81B	4.40B	4.58B	4.58B	4.54B	4.43B	4.04B	7.45B	1.31B	1.22B	1.03B	945.00M	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	75.00M	106.00M	106.00M	114.00M	-542.00M	-495.00M	182.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	9.39B	9.88B	9.86B	10.06B	9.49B	9.38B	9.11B	8.60B	8.95B	8.54B	7.57B	7.33B	7.17B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	10.77B	10.54B	9.56B	9.39B	9.88B	9.93B	10.16B	9.59B	9.50B	8.57B	8.11B	9.13B	8.54B	7.57B	7.33B	7.17B	7.87B	8.02B	8.24B	4.50B	2.47B	2.43B	2.31B	2.02B	1.89B
Other Expenses	6.45B	2.57B	2.53B	2.40B	2.53B	1.70B	1.66B	1.65B	2.23B	3.02B	3.13B	3.02B	3.62B	3.58B	3.14B	-23.00M	3.20B	3.45B	2.93B	-360.73M	-246.94M	-189.64M	-208.00M	-17.00M	995.00M
Operating Expenses	23.94B	19.81B	17.77B	17.32B	18.43B	17.99B	17.39B	16.48B	16.81B	16.25B	15.84B	17.05B	16.97B	15.55B	15.05B	11.72B	15.61B	15.90B	15.21B	11.59B	3.54B	3.46B	3.13B	2.94B	2.89B
Cost & Expenses	38.16B	-7.29B	30.03B	29.48B	30.41B	-7.73B	-7.42B	-7.18B	-7.44B	-5.64B	-5.86B	-7.29B	27.87B	24.27B	22.93B	19.06B	23.20B	23.49B	22.77B	15.34B	4.96B	4.84B	4.38B	4.39B	4.38B
Interest Income	546.00M	206.00M	40.00M	53.00M	141.00M	164.00M	147.00M	68.00M	178.00M	193.00M	109.00M	93.00M	140.00M	105.00M	24.00M	65.00M	190.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	1.09B	461.00M	368.00M	390.00M	444.00M	495.00M	420.00M	924.00M	559.00M	598.00M	609.00M	751.00M	552.00M	467.00M	324.00M	335.00M	329.00M	1.54B	4.71B	2.53B	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	3.78B	3.70B	3.13B	3.27B	3.75B	3.46B	3.15B	2.99B	-2.48B	-2.75B	-3.39B	-3.20B	4.91B	5.44B	5.00B	245.00M	4.48B	6.73B	5.95B	2.52B	117.52M	179.16M	301.00M	241.00M	236.00M
EBITDA	12.00B	14.06B	11.29B	17.51B	7.11B	9.36B	10.28B	10.36B	10.23B	9.87B	9.62B	11.43B	10.64B	11.40B	11.40B	10.48B	10.40B	12.12B	11.67B	2.25B	3.19B	3.00B	2.41B	1.82B	1.21B
EBITDA Ratio	26.06%	30.98%	27.47%	26.13%	26.15%	26.24%	28.38%	29.86%	29.36%	30.84%	30.74%	34.77%	30.35%	35.59%	36.98%	34.73%	35.56%	42.26%	47.01%	14.99%	39.67%	37.49%	37.10%	30.49%	22.56%
Operating Income	7.88B	16.79B	8.13B	8.08B	7.69B	12.43B	12.01B	12.34B	12.71B	12.62B	13.01B	15.70B	5.73B	5.96B	6.37B	9.76B	5.92B	5.73B	7.45B	-262.61M	3.07B	2.62B	2.11B	1.58B	971.00M
Operating Income Ratio	17.11%	37.00%	20.74%	21.63%	20.45%	34.84%	33.15%	35.57%	36.46%	39.45%	41.58%	43.67%	16.35%	18.61%	20.70%	33.88%	20.24%	19.43%	26.13%	-1.75%	38.21%	35.09%	32.46%	26.45%	18.15%
Total Other Income/Expenses	-722.00M	-166.00M	-328.00M	24.00M	-229.00M	228.00M	-188.00M	-720.00M	-403.00M	-458.00M	-459.00M	-1.81B	-542.00M	-362.00M	-300.00M	-232.00M	-139.00M	-981.21M	-2.11B	-588.67M	58.76M	-108.64M	34.00M	-17.00M	-48.00M
Income Before Tax	7.15B	10.49B	7.80B	13.80B	2.82B	4.90B	5.62B	5.81B	5.22B	5.61B	4.52B	6.17B	5.32B	5.60B	6.07B	9.49B	5.78B	4.75B	2.64B	-1.84B	3.13B	2.51B	2.14B	1.56B	0.00
Income Before Tax Ratio	15.54%	23.11%	19.91%	36.94%	7.50%	13.75%	15.50%	16.75%	14.98%	17.52%	14.45%	17.15%	15.17%	17.48%	19.73%	32.94%	19.76%	16.10%	9.27%	-12.25%	38.94%	33.63%	32.98%	26.16%	0.00%
Income Tax Expense	1.60B	2.01B	1.56B	1.81B	139.00M	481.00M	1.72B	1.33B	709.00M	1.21B	726.00M	1.11B	455.00M	1.24B	1.36B	2.76B	687.93M	800.12M	477.04M	818.09M	1.06B	747.13M	842.00M	611.00M	346.00M
Net Income	5.40B	8.37B	6.22B	12.29B	2.81B	4.31B	3.89B	4.71B	4.29B	4.39B	3.72B	4.97B	5.69B	4.36B	5.27B	7.19B	5.27B	4.01B	2.26B	-2.66B	2.07B	1.76B	1.59B	985.00M	625.00M
Net Income Ratio	11.73%	18.44%	15.89%	32.90%	7.46%	12.07%	10.75%	13.57%	12.30%	13.72%	11.88%	13.81%	16.24%	13.60%	17.12%	24.94%	18.02%	13.58%	7.92%	-17.70%	25.80%	23.61%	24.43%	16.52%	11.68%
EPS	4.31	6.69	4.97	9.81	2.33	3.45	3.08	3.42	3.38	3.25	2.75	3.70	4.27	3.34	4.03	2.94	3.91	2.97	1.68	-2.92	2.95	2.42	2.17	1.35	0.85
EPS Diluted	4.30	6.66	4.95	9.76	2.31	3.43	3.07	3.39	3.34	3.21	2.71	3.68	4.26	3.33	4.03	2.94	3.89	2.95	1.67	-2.91	2.95	2.42	2.17	1.35	0.85
Weighted Avg Shares Out	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.27B	1.29B	1.32B	1.32B	1.32B	1.33B	1.32B	1.31B	1.31B	1.31B	1.35B	1.35B	1.34B	910.30M	702.75M	727.69M	731.71M	731.23M	730.78M
Weighted Avg Shares Out (Dil)	1.26B	1.26B	1.26B	1.26B	1.26B	1.26B	1.27B	1.30B	1.32B	1.33B	1.34B	1.33B	1.33B	1.31B	1.31B	1.31B	1.35B	1.36B	1.35B	914.80M	705.12M	729.27M	731.71M	731.23M	730.78M

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

August 14, 2024globenewswire.com

Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi

Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant

August 8, 2024globenewswire.com

Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant

The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi

August 6, 2024zacks.com

AstraZeneca, Ionis and Sanofi are included in this Analyst Blog.

Sanofi to invest 1.3 bln euros in new insulin plant in Frankfurt

August 1, 2024reuters.com

French drugmaker Sanofi will invest 1.3 billion euros ($1.40 billion) in a new insulin production facility at its existing site in Frankfurt, where it makes insulin brand Lantus, the company said on Thursday.

Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal

July 26, 2024seekingalpha.com

Novavax's Q1 2024 earnings were so-so, but a major partnership with Sanofi sent its share price soaring by 200%. The Sanofi deal provides essential funding but restricts Novavax's future earning potential, making it reliant on revenue streams from Sanofi. Novavax's...

Sanofi (SNY) Q2 2024 Earnings Call Transcript

July 25, 2024seekingalpha.com

Sanofi (NASDAQ:SNY ) Q2 2024 Q2 2024 Earnings Conference Call July 25, 2024 8:30 AM ET Company Participants Thomas Kudsk - Investor Relations Paul Hudson - Chief Executive Officer François Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian...

Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised

July 25, 2024zacks.com

Sanofi (SNY) posts mixed quarterly results, beating estimates for earnings while missing the same for sales. It raises its 2024 earnings growth expectations at CER.

Press Release: Online availability of Sanofi's half-year financial report for 2024

July 25, 2024globenewswire.com

Online availability of Sanofi's half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available and has been filed with the French market regulator Autorité...

Sanofi bumps up full-year forecast after strong Q2 profit

July 25, 2024reuters.com

Sanofi's second-quarter profit rose 3.2% on strong demand for its blockbuster asthma drug Dupixent and better-than-expected sales of new launches, with the company now expecting a stable full-year profit compared to a prior forecast of a fall.